Publikation

ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.

Wissenschaftlicher Artikel/Review - 19.10.2023

Bereiche
PubMed
DOI
Kontakt

Zitation
O'Dowd E, Tietzova I, Bartlett E, Devaraj A, Biederer J, Brambilla M, Brunelli A, Chorostowska-Wynimko J, Decaluwe H, Deruysscher D, De Wever W, Donoghue M, Fabre A, Gaga M, van Geffen W, Hardavella G, Kauczor H, Kerpel-Fronius A, van Meerbeeck J, Nagavci B, Nestle U, Novoa N, Prosch H, Prokop M, Putora P, Rawlinson J, Revel M, Snoeckx A, Veronesi G, Vliegenthart R, Weckbach S, Blum T, Baldwin D. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer. Eur Respir J 2023; 62
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Eur Respir J 2023; 62
Veröffentlichungsdatum
19.10.2023
eISSN (Online)
1399-3003
Kurzbeschreibung/Zielsetzung

Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that will ensure clinical and cost effectiveness. This European Respiratory Society (ERS) task force was formed to provide an expert consensus for the management of incidental findings which can be adapted and followed during implementation.